Decreased muscle mass and function,also known as sarcopenia,is common in patients with cirrhosis and is associated with a poor prognosis.Although the pathogenesis of this disorder has not been fully elucidated,a disor...Decreased muscle mass and function,also known as sarcopenia,is common in patients with cirrhosis and is associated with a poor prognosis.Although the pathogenesis of this disorder has not been fully elucidated,a disordered gutmuscle axis probably plays an important role.Decreased barrier function of the gut and liver,gut dysbiosis,and small intestinal bacterial overgrowth(SIBO)can lead to increased blood levels of ammonia,lipopolysaccharides,pro-inflammatory mediators,and myostatin.These factors have complex negative effects on muscle mass and function.Drug interventions that target the gut microbiota(long-term use of rifaximin,lactulose,lactitol,or probiotics)positively affect most links of the compromised gut-muscle axis in patients with cirrhosis by decreasing the levels of hyperammonemia,bacterial translocation,and systemic inflammation and correcting gut dysbiosis and SIBO.However,although these drugs are promising,they have not yet been investigated in randomized controlled trials specifically for the treatment and prevention of sarcopenia in patients with cirrhosis.No data exist on the effects of fecal transplantation on most links of gut-muscle axis in cirrhosis;however,the results of animal experimental studies are promising.展开更多
文摘Decreased muscle mass and function,also known as sarcopenia,is common in patients with cirrhosis and is associated with a poor prognosis.Although the pathogenesis of this disorder has not been fully elucidated,a disordered gutmuscle axis probably plays an important role.Decreased barrier function of the gut and liver,gut dysbiosis,and small intestinal bacterial overgrowth(SIBO)can lead to increased blood levels of ammonia,lipopolysaccharides,pro-inflammatory mediators,and myostatin.These factors have complex negative effects on muscle mass and function.Drug interventions that target the gut microbiota(long-term use of rifaximin,lactulose,lactitol,or probiotics)positively affect most links of the compromised gut-muscle axis in patients with cirrhosis by decreasing the levels of hyperammonemia,bacterial translocation,and systemic inflammation and correcting gut dysbiosis and SIBO.However,although these drugs are promising,they have not yet been investigated in randomized controlled trials specifically for the treatment and prevention of sarcopenia in patients with cirrhosis.No data exist on the effects of fecal transplantation on most links of gut-muscle axis in cirrhosis;however,the results of animal experimental studies are promising.
